利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.017 秒)

    MAGNETIC CIRCUIT FOR PRODUCING A CONCENTRATED MAGNETIC FIELD
    2.
    发明公开
    MAGNETIC CIRCUIT FOR PRODUCING A CONCENTRATED MAGNETIC FIELD 审中-公开
    MAGNETISCHE SCHALTUNG ZUR ERZEUGUNG EINES KONZENTRIERTEN MAGNETFELDES

    公开(公告)号：EP3149503A1

    公开(公告)日：2017-04-05

    申请号：EP15802613.8

    申请日：2015-06-02

    申请人： Monash University ,  Alfred Health

    发明人： PREMARATNE, Malin ,  HANDAPANGODA, Chintha ,  FITZGERALD, Paul ,  LEWIS, Philip ,  THOMSON, Richard

    IPC分类号： G01R33/00 ,  G01R33/02

    CPC分类号： H01F7/20 ,  A61N2/006 ,  A61N2/02 ,  G01R33/0011 ,  H01F1/14708 ,  H01F7/064

    摘要： A magnetic circuit (400) comprises a magnetic path which includes at least one magnetic source (102) arranged to generate magnetic flux within the magnetic path. A magnetic flux-concentrating element 402 is magnetically coupled to the magnetic source, and arranged to concentrate magnetic-flux generated by the magnetic source within a volume adjacent to the magnetic flux-concentrating element (402). Some embodiments of the magnetic circuit (400) comprise at least first (102) and second (104) magnetic sources, which may advantageously be arranged to generate magnetic flux in a common direction within the magnetic path.

    摘要翻译： 磁路（400）包括磁路，该磁路包括布置成在磁路内产生磁通量的至少一个磁源（102）。 磁通量集中元件402磁耦合到磁源，并且被布置成将由磁源产生的磁通集中在与磁通量集中元件（402）相邻的体积内。 磁路（400）的一些实施例包括至少第一（102）和第二（104）磁源，其可以有利地布置成在磁路内沿公共方向产生磁通量。

    MONITORING TREATMENT OR PROGRESSION OF MYELOMA
    6.
    发明公开
    MONITORING TREATMENT OR PROGRESSION OF MYELOMA 审中-公开

    公开(公告)号：EP3384050A1

    公开(公告)日：2018-10-10

    申请号：EP16869417.2

    申请日：2016-12-02

    申请人： Alfred Health

    发明人： SPENCER, Andrew ,  MITHRAPRABHU, Sridurga

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/156

    摘要： The present invention relates to methods and kits for diagnosing myeloma, monitoring disease progression or treatment efficacy in an individual having a myeloma. In one aspect, the invention relates to A method for monitoring the response of an individual to treatment for multiple myeloma, the method comprising providing cell-free nucleic acids derived from a sample of peripheral blood from an individual that has undergone treatment for multiple myeloma; assessing the cell-free nucleic acids for a mutation in any one or more nucleotide sequences from a KRAS, NRAS, BRAF and/or TP53 gene; wherein an absence of, or reduction in the number of, mutations in a nucleotide sequence from a KRAS, NRAS, BRAF and/or TP53 gene indicates a response of the individual to treatment for multiple myeloma.

    METHOD FOR DIAGNOSIS, PROGNOSIS OR TREATMENT OF ACUTE CORONARY SYNDROME (ACS) COMPRISING MEASUREMENT OF PLASMA CONCENTRATION OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)
    8.
    发明公开
    METHOD FOR DIAGNOSIS, PROGNOSIS OR TREATMENT OF ACUTE CORONARY SYNDROME (ACS) COMPRISING MEASUREMENT OF PLASMA CONCENTRATION OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) 审中-公开
    用于诊断，预后或急性冠状动脉综合征（ACS）方法测量血浆浓度MACRO PHAG迁移抑制因子作者：装置（MIF）

    公开(公告)号：EP2742348A1

    公开(公告)日：2014-06-18

    申请号：EP11870922.9

    申请日：2011-08-12

    申请人： Alfred Health ,  Baker IDI Heart and Diabetes Institute Holdings Ltd

    发明人： DART, Anthony

    IPC分类号： G01N33/49

    CPC分类号： G01N33/573 ,  G01N27/28 ,  G01N33/6863 ,  G01N2800/324

    摘要： The invention relates to a method for diagnosing acute coronary syndrome (ACS) in a subject, the method comprising measuring plasma macrophage migration inhibitory factor (MIF) concentration in a sample from the subject, and diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, wherein the sample is taken less than 4 hours after symptom onset. The invention also relates to a method for prognosing ACS in a subject, the method comprising measuring plasma MIF concentration in a sample from the subject, diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, and prognosing the magnitude of ACS from the subject plasma MIF concentration. Also provided is a method of treating ACS in a subject, a device, a kit, and a cardiac biomarker related to the methods of diagnosing and prognosing ACS.